Clearmind Medicine Reports Positive Phase I/IIa Results for CMND-100 in Alcohol Use Disorder Trial
I'm PortAI, I can summarize articles.
Clearmind Medicine Inc. reported positive results from its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, conducted at prestigious institutions like Yale and Johns Hopkins, has shown favorable safety and tolerability with no serious adverse events. The Data and Safety Monitoring Board approved the trial's continuation after an interim review. Enrollment and dosing for the second cohort are complete, with more data expected in the future.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments